Download PDF
Seminars in Neurosurgery 2002; 13(3): 245-256
DOI: 10.1055/s-2002-39818
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Adjunctive Use of Abciximab during Cerebrovascular Angioplasty and Stenting

Rocco A. Armonda1,2,3,4 , Ronald Benitz4 , Robert H. Rossenwasser4
  • 1Division of Cerebrovascular Surgery and Interventional Neuroradiology, National Capital Consortium, Washington, D.C
  • 2Neurosurgery Service, Walter Reed Army Medical Center, Washington, D.C
  • 3National Naval Medical Center and Division of Cerebrovascular Surgery and Interventional Neuroradiology
  • 4Thomas Jefferson University and Wills Neurosensory Institute, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
24 June 2003 (online)

    Permissions and Reprints

ABSTRACT

The incidence of periprocedural neurological events in patients undergoing carotid angioplasty and stenting varies from 3 to 13%. During the period from April 1996 to February 1, 2000, a total of 47 patients underwent cerebrovascular angioplasty, with stenting in 44 patients. In this group of patients 24 patients had the perioperative administration of abciximab. The abciximab group underwent 24 carotid angioplasties and stenting (CAS) procedures, one vertebral origin, and one intracranial vertebral artery angioplasty and stenting. This population was compared with a non-abciximab group of 23 patients undergoing 24 CAS procedures and two angioplasties alone, without abciximab. This preliminary report has demonstrated the feasibility of the use of abciximab in this small patient sample with encouraging ea rly results [non-abcixmab group: 17.3% (13% resolved in 24 hours, 4.3% > 24 hour stroke rate, and 4.3% mortality vs abciximab group: 4.1% stroke rate, 0% mortality with a 4.1% intracranial hemorrhage not requiring surgical intervention).

KEYWORDS

Abciximab - carotid stenting - neurological risks

REFERENCES

  • 1 Connors J J, Seidenwurm D, Wojak J C. et al . Treatment of atherosclerotic disease at the cervical carotid bifurcation: current status and review of the literature.  Am J Neuroradiol . 2000;  21 444-450
    PubMedGoogle Scholar
  • 2 Mericle R A, Kim S H, Lanzino G. et al . Carotid artery angioplasty and use of stents in high-risk patients with contralateral occlusions.  J Neurosurg . 1999;  90 1031-1036
    PubMedGoogle Scholar
  • 3 Yadav J S, Roubin G S, Iyer S. Elective stenting of the extracranial carotid arteries.  Circulation . 1997;  95 376-381
    CrossrefPubMedGoogle Scholar
  • 4 Teitelbaum G P, Lefkowitz M A, Giannotta S L. Carotid angioplasty and stenting in high-risk patients.  Surg Neurol . 1998;  50 300-312
    PubMedGoogle Scholar
  • 5 Wholey M H, Wholey M, Bergeron P. et al . Current global status of carotid stent placement.  Catheterization and Cardiovascular Diagnosis . 1998;  44 1-6
    CrossrefPubMedGoogle Scholar
  • 6 Mathur A, Roubin G, Gomez C R. et al . Elective carotid artery stenting in the presence of contralateral occlusion.  Am J Cardiol . 1998;  81 1315-1317
    CrossrefPubMedGoogle Scholar
  • 7 Al-Mubarak N, Roubin G S, Gomez C R. et al . Carotid artery stenting in patients with high neurologic risks.  Am J Cardiol . 1999;  83 1411-1413
    CrossrefPubMedGoogle Scholar
  • 8 Al-Mubarak N, Roubuin G S, Liu M W. et al . Early results of percutaneous intervention for severe coexisting carotid and coronary artery disease.  Am J Cardiol . 1999;  84 600-602
    CrossrefPubMedGoogle Scholar
  • 9 New G, Roubin G S, Iyer S S, Vitek J J. Carotid artery stenting: rationale, indications, and results.  Comp Ther . 1999;  25 438-445
    PubMedGoogle Scholar
  • 10 Morris P, Martin E M, Braden G. Intracranial deployment of coronary stents for symptomatic atherosclerotic disease.  Am J Neuroradiol . 1999;  20 1688-1694
    PubMedGoogle Scholar
  • 11 Quereshi A I, Luft A R, Janardhan V. et al . Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting.  Stroke . 2000;  31 376-382
    CrossrefPubMedGoogle Scholar
  • 12 Jeong M H, Owen W G, Staab M E. et al . Porcine model of stent thrombosis: platelets are the primary component of acute stent closure.  Cathet Cardiovascular Diagn . 1996;  38 38-43
    PubMedGoogle Scholar
  • 13 Kapadia S R, Bajzer C I, Ziada K M. et al .Initial experience of glycoprotien IIb/IIIa inhibition with abciximab during carotid stenting: a safe adjunctive therapy. Abstracts Angiography and Interventional Cardiology, ACCIS 2000, JAAC 86A Feb 2000
    Google Scholar
  • 14 Horwitz A. Integrins and health.  Scientific American . 1997;  68-75
    PubMedGoogle Scholar
  • 15 The Abciximab in Ischemic Stroke Investigators. Abciximab in ischemic stroke: a randomized, double blind, placebo-controlled, dose-escalation study.  Stroke . 2000;  31 601-609
    CrossrefPubMedGoogle Scholar
  • 16 Abumiya T, Lucero J, Heo H J. et al . Activated microvessels expressed vascular endothelial growth factor and integrin alphaVbetaIII during focal cerebral ischemia.  J Cerebral Blood Flow and Metabolism . 1999;  19 1038-1050
    PubMedGoogle Scholar
  • 17 DeGraba T J, Siren A L, Penix L. et al . Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque.  Stroke . 1998;  29 1405-1410
    PubMedGoogle Scholar
  • 18 Ross R. Atherosclerosis: an inflammatory disease.  N Engl J Med . 1999;  340 115-126
    CrossrefPubMedGoogle Scholar
  • 19 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med . 1999;  20 1555-1564
    PubMedGoogle Scholar
  • 20 The EPIC Investigators. The use of a monoclonal antibody directed against the platelet glyocoprotein IIb/IIIa receptor in high-risk coronary angioplasty.  N Engl J Med . 1994;  330 956-961
    CrossrefPubMedGoogle Scholar
  • 21 Kereiakes D J. Oral blockade of the platelet glycoprotien IIb/IIIa receptor: fact or fancy?.  American Heart Journal. 138 S39-S46
    PubMedGoogle Scholar
  • 22 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizations.  N Engl J Med . 1997;  336 1689-1696
    CrossrefPubMedGoogle Scholar
  • 23 The Epistent Investigators. Randomized placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb/ IIIa blockade.  Lancet. 352 87-92
    PubMedGoogle Scholar
  • 24 Topol E J, Califf R M, Weisman H F. et al . Randomized trial of coronary interventions with an antibody against platelet IIb/ IIIa integrin for reduction of clinical restenosis.  Lancet . 1994;  343 881-886
    CrossrefPubMedGoogle Scholar
  • 25 Gibson C M, Murphy S A, Rizzo M J. et al . Relationship between TIMI frame count and clinical outcomes after thrombolytic administration.  Circulation . 1999;  1945-1950
    PubMedGoogle Scholar
  • 26 Farb A, Sangiorgi G, Carter A J. et al . Pathology of acute and chronic coronary stenting in humans.  Circulation . 1999;  99 44-52
    PubMedGoogle Scholar
  • 27 Peipgras D G, Morgan M K, Sundt T M. et al . Intracerebral hemorrhage after carotid endarterectomy.  J Neurosurg . 1988;  68 532-536
    PubMedGoogle Scholar
  • 28 Sundt T M, Sandok B A, Whisnant J P. Carotid endarterectomy: complications and preoperative assessment of risk.  Mayo Clinic Proceedings . 1975;  50 301-306
    PubMedGoogle Scholar
  • 29 Mori T, Fukuoka M, Kazita K, Mima T, Mori K. Intraventricular hemorrhage after carotid stenting.  J Endovascular Surgery . 1999;  6 337-341
    PubMedGoogle Scholar
  • 30 Qureshi A I, Saadf M, Zaidat O O. et al . Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab.  Stroke . 2002;  33 1916-1919
    CrossrefPubMedGoogle Scholar
  • 31 Willfort-Ehringer A, Ahmadi R, Gschwandtner M, Haumer M, Lang W, Minar E. Single-center experience with carotid stent restenosis.  J Endovascular Ther . 2002;  9 299-307
    PubMedGoogle Scholar
  • 32 Hofmann R, Kerschner K, Steinwender C, Kypta A, Dietmar B, Leisch F. Abciximab bolus injection does not reduce cerebral ischemic complication of elective carotid artery stenting: a randomized study.  Stroke . 2002;  33 725-727
    CrossrefPubMedGoogle Scholar
  • 33 Schneiderman J, Morag B, Gerniak A. et al . Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.  J Endovasc Ther . 2000;  7 263-272
    CrossrefPubMedGoogle Scholar
      >